Ascentage Pharma

65 articles with Ascentage Pharma

• Ascentage Pharma Presents Updates on its Global Clinical Development at the J.P. Morgan 39th Annual Healthcare Conference

  1/13/2021

  Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, presented at the J.P. Morgan 39th Annual Healthcare Conference (a virtual event) in the evening of January 13, Beijing Time

• Ascentage Pharma Announces its 9th Orphan Drug Designation from the US FDA in 2020, Setting a Record for Chinese Biopharmaceutical Companies

  1/5/2021

  Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the US Food and Drug Administration (FDA) has granted an Orphan Drug Designation (ODD) to the company's

• Ascentage Pharma Officially Included in Shenzhen-Hong Kong Stock Connect Program

  12/30/2020

  Ascentage Pharma, a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases, announced that the company was officially included into the Shenzhen-Hong Kong Stock Connect program.

• Ascentage Pharma's Licensee UNITY Biotechnology Announces Milestone Reached in Clinical Development of Treatments for Age-Related Disease, Leading to Milestone Payment

  12/22/2020

  Ascentage Pharma, a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases, announced that its licensee, UNITY Biotechnology, has dosed the first patient in a Phase I clinical study of drug candidate UBX1325 in patients with diabetic macular edema.

• Ascentage Pharma Announces Positive Data from Pivotal Phase II Studies of HQP1351 (Olverembatinib) in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML) at 2020 American Society of Hematology (ASH) Annual Meeting

  12/7/2020

  Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today reported positive data from two pivotal Phase II clinical trials of HQP1351 (olverembatinib) in an oral presentation at the 62nd ASH Annual Meeting.

• Ascentage Pharma Appoints Mr. Gang Zhu as Chief Commercial Officer to Lead Commercial Initiatives

  12/3/2020

  Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced the appointment of Mr. Gang Zhu

• Ascentage Pharma Enters into an Agreement with University of Michigan to obtain an exclusive license for a MDM2 Degrader using PROTAC Technology

  11/30/2020

  Ascentage Pharma announced it has entered into an agreement with the University of Michigan, through which the company may obtain the exclusive global rights to a MDM2 protein degrader developed using the Proteolysis-Targeting Chimeras technology.

• Ascentage Pharma Announces First Patient Dosed in Europe in the Phase Ib/II Study of the Bcl-2 inhibitor APG-2575 in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  11/24/2020

  Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that a Phase Ib/II clinical study of the company's novel Bcl-2 inhibitor APG-2575,

• Ascentage Pharma Receives Approvals for Two Phase Ib/II Clinical Studies of the Bcl-2 Inhibitor APG-2575 for the Treatment of Waldenström Macroglobulinemia and Multiple Myeloma in China

  11/23/2020

  Ascentage Pharma announced that the Center for Drug Evaluation of China National Medical Products Administration has approved two Phase Ib/II clinical studies of its novel Bcl-2 inhibitor APG-2575; one for APG-2575 as a single agent or in combination with ibrutinib/rituximab for the treatment of patients with Waldenström macroglobulinemia, and the other one for APG-2575 as a single agent or in combination with lenalidomide/dexamethasone for the treatment of patients with multiple myeloma.

• Ascentage Pharma to Release Updated Clinical Results of HQP1351 (Olverembatinib) in Drug-Resistant Chronic Myeloid Leukemia in an Oral Presentation at the American Society of Hematology Annual Meeting

  11/9/2020

  Ascentage Pharma announced that the results from two pivotal Phase II studies of the company's novel BCR-ABL inhibitor, HQP1351, have been accepted for oral presentation at the 62nd American Society of Hematology Annual Meeting.

• Ascentage Pharma Announces Approval for the Phase Ib/II Clinical Study of MDM2-p53 Inhibitor APG-115 in Combination with Immunotherapy for the Treatment of Patients with Advanced Liposarcoma or other Advanced Solid Tumors in China

  10/27/2020

  Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has approved a Phase Ib/II study of Ascentage Pharma's novel MDM2-p53 inhibitor APG-115

• Priority Review Granted to Ascentage Pharma's New Drug Application for Olverembatinib (HQP1351), the First Third-Generation BCR-ABL Inhibitor in China

  10/21/2020

  Ascentage Pharma announced that the Center for Drug Evaluation of China's National Medical Products Administration has granted Guangzhou Healthquest Pharma Co., Ltd, a wholly-owned subsidiary of the company, priority review to its New Drug Application for Olverembatinib.

• Ascentage Pharma's Apoptosis-Targeting Drug Candidates Granted Two More Orphan Drug Designations by the US FDA

  10/9/2020

  Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the US Food and Drug Administration (FDA) has granted two Orphan Drug Designations (ODDs) to two of the

• Ascentage Pharma's MDM2-p53 Inhibitor APG-115 Granted Orphan Drug Designation by the FDA for the Treatment of Gastric Cancer

  9/14/2020

  Ascentage Pharma, a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases, announced that the US Food and Drug Administration has granted APG-115, a novel MDM2-p53 inhibitor being developed by the company, an Orphan Drug Designation for the treatment of gastric cancer.

• Ascentage Pharma's Bcl-2 Inhibitor APG-2575 Granted Orphan Drug Designation by the FDA for the Treatment of Chronic Lymphocytic Leukemia

  9/7/2020

  Ascentage Pharma, a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases, announced that the US Food and Drug Administration has granted APG-2575, a novel Bcl-2 inhibitor being developed by the company, an Orphan Drug Designation for the treatment of chronic lymphocytic leukemia.

• Ascentage Pharma Releases Preclinical Results of IAP Antagonist APG-1387 in an Oral Presentation at EASL ILC 2020

  8/27/2020

  Ascentage Pharma announced that preclinical study results of the company's novel inhibitor of apoptosis proteins antagonist APG-1387 in the treatment of CHB infection have been presented in an oral presentation at the Digital International Liver Congress™ 2020 held by the European Association for the Study of the Liver.

• Ascentage Pharma Releases 2020 Interim Results, Reporting the Company's First New Drug Application and Advances in Global Strategic Collaborations

  8/18/2020

  Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its interim results for the six months ended June 30, 2020 . During the reporting period, Ascentage Pharma m

• Ascentage Pharma Becomes a Constituent of Three Major Indexes Including Hang Seng Composite Index

  8/17/2020

  Ascentage Pharma announced that the company has been selected as a constituent stock of the Hang Seng Composite Index, the Hang Seng Hong Kong-Listed Biotech Index and the Hang Seng Healthcare Index in accordance with the quarterly adjustment results of the latest index series released by Hang Seng Indexes Company Limited, with effect from September 7th, 2020.

• Ascentage Pharma Announces First Patient Dosed in the Phase Ib Study of MDM2-p53 Inhibitor APG-115 as Single Agent and in Combinations for the Treatment of Hematologic Malignancies in China

  7/22/2020

  Ascentage Pharma announced that the Phase Ib study of the company's novel MDM2-p53 inhibitor candidate APG-115 as a single agent or in combinations for the treatment of Chinese patients with relapsed/refractory acute myeloid leukemia, or relapsed/progressed high/very high risk myelodysplastic syndrome has dosed its first patient in China.

• Ascentage Pharma's Bcl-2 Inhibitor APG-2575 Granted Orphan Drug Designation by the FDA for the Treatment of Waldenström Macroglobulinemia

  7/15/2020

  Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the US Food and Drug Administration (FDA) has granted APG-2575, a novel Bcl-2 inhibitor being developed by